Gelonghui, May 28, 丨 Lu Hang Pharmaceutical (600789.SH) announced that the company's holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (“SAITE”) has received a “Drug Registration Certificate” (approval number: 2024S00910) for doxofylline injections (referred to as “this drug”) issued by the State Drug Administration.
Doxofylline is a novel derivative of methylxanthine. It is a bronchodilator that acts directly on the bronchi to relax bronchial smooth muscle. By inhibiting effects such as phosphodiesterase in smooth muscle cells, it relaxes smooth muscle, thereby achieving the effect of suppressing asthma. Clinical application has proven that doxofylline has the characteristics of long half-life, strong anti-asthma effect, and good tolerability. The therapeutic effect is superior to traditional theophylline drugs, and it is a drug with good clinical application prospects. It is suitable for treating bronchial asthma and lung diseases with bronchospasm components.